Actinium Pharmaceuticals Seeks to Expand Pipeline with Innovative Myeloma Treatment

Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) announced that it has begun Phase 1 clinical trials to study Actimab-M in the treatment of multiple myeloma.

Keep Reading →